Drug intelligence / Profile preview

CD45RA-depleted peripheral blood mononuclear cells

Development stage
Phase 2
Lead developer
Miltenyi Biotec
Modality
Cell Therapies, Vaccines & Immunotherapeutics
Administration
Intravenous
01

Overview

CD45RA-depleted peripheral blood mononuclear cells are a specialized cellular therapy product created by selectively removing CD45RA-positive cells (primarily naive T cells) from donor peripheral blood mononuclear cells (PBMCs), resulting in a preparation enriched with memory T cells that can fight infections while reducing the risk of graft-versus-host disease (GVHD). ## Description CD45RA-depleted peripheral blood mononuclear cells are a cellular therapy product created through immunomagnetic depletion of CD45RA-positive cells from donor peripheral blood mononuclear cells. This selective depletion process removes naive T cells (TN) while preserving memory T cells (TM) that have specificity for common opportunistic pathogens[1][6]. The resulting cellular product contains a high amount of memory T cells that can provide protection against viral infections (such as cytomegalovirus, Epstein-Barr virus, and adenovirus) and fungal infections (such as Aspergillus)[5][7]. This approach has been shown to enhance early T-cell recovery and significantly reduce both the incidence and duration of viremia in transplant recipients[1]. The depletion process is performed using GMP-grade murine αCD45RA monoclonal antibody directly conjugated to Miltenyi iron dextran beads, which allows for the selective removal of CD45RA+ cells while preserving CD34+ hematopoietic stem cells and functional memory T cells[7]. Clinical studies have demonstrated that recipients of CD45RA-depleted grafts had significantly higher T-cell counts at Day +30 post-transplant (550/μL vs 10/μL) and higher T-cell diversity compared to recipients of conventional T-cell depleted grafts[1]. This approach has been particularly valuable in the context of haploidentical hematopoietic cell transplantation, where it provides a safer alternative to conventional T-cell depletion methods[1][5].

Other names
CD45RA-depleted donor T lymphocytesCD-45RA-depleted donor T lymphocytesCD 45RA-depleted donor T lymphocytesCD45RA-depleted PBMCsCD-45RA-depleted PBMCsCD 45RA-depleted PBMCsCD45RA-depleted T cellsCD-45RA-depleted T cellsCD 45RA-depleted T cellsCD45RA- T cellsCD-45RA- T cellsCD 45RA- T cellsmemory T cell-enriched donor lymphocytes
02

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on CD45RA-depleted peripheral blood mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD45RA-depleted peripheral blood mononuclear cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call